Literature DB >> 3280212

Clinical pharmacokinetics of amantadine hydrochloride.

F Y Aoki1, D S Sitar.   

Abstract

Amantadine is a drug with diverse uses ranging from prevention of influenza A illness to the treatment of patients with Parkinson's disease. It is available only in oral formulations from which it is well absorbed and widely distributed, little drug being present in the circulation. Apparent volume of distribution is inversely related to dose over the therapeutic range and accounts in part for a noteworthy logarithmic increase in plasma concentration as a function of dose. Elimination is primarily by renal clearance by both glomerular filtration and tubular secretion. Amantadine accumulates in patients with renal dysfunction. Hence, doses must be reduced in such patients to avoid toxicity. Interactions with other drugs appear uncommon. Relationships have been demonstrated between amantadine therapeutic effects and plasma concentrations in different study cohorts, but not in individual patients. Dose schedules have been suggested for individuals in whom amantadine kinetics are different from healthy subjects. However, these schedules are controversial in their choice of target concentrations and in being untested as to predictive value.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280212     DOI: 10.2165/00003088-198814010-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  71 in total

1.  Toxic effects of amantadine in patients with renal failure.

Authors:  T S Ing; J T Daugirdas; L S Soung; H L Klawans; S D Mahurkar; J A Hayashi; W P Geis; J E Hano
Journal:  Can Med Assoc J       Date:  1979-03-17       Impact factor: 8.262

2.  Amantadine toxicity in a patient with renal insufficiency.

Authors:  K F Armbruster; A C Rahn; T S Ing; I S Halper; J H Oyama; H L Klawans
Journal:  Nephron       Date:  1974       Impact factor: 2.847

3.  A field trial of amantadine prophylaxis in naturally-occurring acute respiratory illness.

Authors:  J F Finklea; A V Hennessy; F M Davenport
Journal:  Am J Epidemiol       Date:  1967-05       Impact factor: 4.897

4.  [Gaschromatographic and mass spectrometric studies on metabolites of adamantane amines excreted with urine (author's transl)].

Authors:  W Wesemann; J D Schollmeyer; G Sturm
Journal:  Arzneimittelforschung       Date:  1977-07

Review 5.  Extracorporeal therapy in the treatment of intoxication.

Authors:  E Blye; J Lorch; S Cortell
Journal:  Am J Kidney Dis       Date:  1984-03       Impact factor: 8.860

6.  Gas chromatographic determination of amantadine hydrochloride (Symmetrel) in human plasma and urine.

Authors:  A Sioufi; F Pommier
Journal:  J Chromatogr       Date:  1980-07-11

7.  Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.

Authors:  G M Pacifici; M Nardini; P Ferrari; R Latini; C Fieschi; P L Morselli
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

8.  Antagonism of ethanol-evoked responses by amantadine: a possible clinical application.

Authors:  F S Messiha
Journal:  Pharmacol Biochem Behav       Date:  1978-05       Impact factor: 3.533

9.  Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults.

Authors:  F G Hayden; J M Gwaltney; R L Van de Castle; K F Adams; B Giordani
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

10.  On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride.

Authors:  J J Skehel; A J Hay; J A Armstrong
Journal:  J Gen Virol       Date:  1978-01       Impact factor: 3.891

View more
  35 in total

Review 1.  Managing antipsychotic-induced parkinsonism.

Authors:  D C Mamo; R A Sweet; M S Keshavan
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

2.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

3.  Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.

Authors:  Eric Brantley; Jamieson Cohn; Kavita Babu
Journal:  J Med Toxicol       Date:  2009-06

Review 4.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 5.  Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

Review 6.  Drug interactions with antiviral drugs.

Authors:  A M Taburet; E Singlas
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

7.  Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus.

Authors:  Brenda L Fredericksen; Bangdong L Wei; Jian Yao; Tianci Luo; J Victor Garcia
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 8.  Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction.

Authors:  Heath D Schmidt; R Christopher Pierce
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

9.  Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects.

Authors:  L T Wong; D S Sitar; F Y Aoki
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

10.  Cardiotoxicity after massive amantadine overdose.

Authors:  Michael Schwartz; Manish Patel; Ziad Kazzi; Brent Morgan
Journal:  J Med Toxicol       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.